Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine entities : Curevac n.v. save search
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 2.79%
H: 2.03%
C: 0.34%
vaccine influenza collaboration program
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 0.71%
H: 4.24%
C: 2.12%
covid-19 vaccine positive collaboration program technology platform
Global mRNA Vaccine Market Research Report 2023-2028: COVID-19 Success Opens New Avenues with with 444 Ongoing Clinical Studies Worldwide
Published: 2023-11-08 (Crawled : 03:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: 1.91%
H: 0.0%
C: 0.0%
VERV | $6.88 -0.43% -0.44% 970K
|
Professional, Scientific, and T...
|
| O: 0.37%
H: 0.64%
C: -10.76%
GSK | News | $41.24 1.6% 0.0% 1.6K
|
Health Technology
|
| O: 0.46%
H: 0.46%
C: -0.23%
MRNA | News S | $107.89 3.28% 3.87% 33K
|
Health Technology
|
| O: -0.01%
H: 0.03%
C: -3.14%
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 0.91%
H: 1.08%
C: -1.44%
BNTX | News | $88.49 0.55% 0.59% 1K
|
Health Technology
|
| O: 0.13%
H: 0.08%
C: -2.81%
ARCT 4 | $27.93 3.22% 3.11% 1
|
Health Technology
|
| O: -0.36%
H: 0.79%
C: -0.61%
covid-19 success report vaccine mrna worldwide ongoing research global market
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: -0.47%
H: 0.62%
C: -3.79%
candidate vaccine mrna collaboration study
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Published: 2023-08-01 (Crawled : 14:20) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: -0.86%
H: 0.65%
C: -1.2%
covid-19 vaccine mrna collaboration study
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
Published: 2023-06-20 (Crawled : 12:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: -0.1%
H: 18.18%
C: 12.12%
candidate vaccine cancer glioblastoma study
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Published: 2023-05-08 (Crawled : 12:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 0.0%
H: 4.98%
C: 2.55%
vaccine influenza collaboration study
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
Published: 2023-01-30 (Crawled : 15:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 5.36%
H: 4.0%
C: -3.5%
covid-19 vaccine mrna positive
mRNA Vaccine Market to Reach $91.14 Billion by 2029
Published: 2023-01-24 (Crawled : 13:20) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.27%
H: 0.1%
C: 0.1%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
SGMO | News | $0.5209 2.12% 2.13% 2.3M
|
Health Technology
|
| O: -0.87%
H: 1.76%
C: 1.17%
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: -2.14%
H: 4.07%
C: 1.49%
vaccine mrna market
Global Messenger RNA (mRNA) Vaccines & Therapeutics Markets, 2022-2023 & 2028: Rising Demand for Therapeutic Drugs and Vaccines for Ebola, influenza, HIV, and Other Viral Illnesses
Published: 2023-01-06 (Crawled : 00:20) - prnewswire.com
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
| Email alert
Add to watchlist
global therapeutics vaccine hiv
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
Published: 2023-01-06 (Crawled : 17:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 12.7%
H: 15.44%
C: 14.88%
covid-19 vaccine mrna positive
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Published: 2022-08-18 (Crawled : 12:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: -0.61%
H: 1.64%
C: -4.58%
covid-19 candidate vaccine study phase 1
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
Published: 2022-05-25 (Crawled : 13:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: -1.43%
H: 1.08%
C: -5.61%
vaccine cancer
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
Published: 2022-04-21 (Crawled : 12:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 4.87%
H: 0.0%
C: 0.0%
preclinical vaccine mrna sars-cov-2 pre-clinical
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
Published: 2022-03-30 (Crawled : 12:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 0.0%
H: 1.56%
C: 0.52%
covid-19 cv2cov vaccine
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
Published: 2022-02-10 (Crawled : 12:30) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 2.16%
H: 3.12%
C: -4.13%
bone one phase 1 collaboration vaccine influenza
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
Published: 2021-10-12 (Crawled : 12:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: -13.04%
H: 13.08%
C: 9.7%
covid vaccine technology covid-19
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Published: 2021-09-17 (Crawled : 14:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
MRNA | News S | $107.89 3.28% 3.87% 33K
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: 0.0%
BNTX | News | $88.49 0.55% 0.59% 1K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: 0.0%
covid cancer vaccine technology covid-19
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
Published: 2021-06-30 (Crawled : 22:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 3.28%
H: 9.4%
C: 5.47%
covid phase 2 vaccine phase 2b trial cv2cov
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
Published: 2021-06-16 (Crawled : 23:00) - biospace.com/
CVAC | $2.6 2.77% 2.13% 590K
|
Health Technology
|
| O: 0.57%
H: 2.27%
C: -4.02%
covid phase 2 vaccine phase 2b trial cv2cov covid-19
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
Your saved searches
Save your searches and get alerts when important news are released.